https://www.biospace.com/employer/3045045/first-tracks-biotherapeutics First Tracks Biotherapeutics en-US Thu, 11 Dec 2025 10:19:11 GMT https://www.biospace.com/drug-development/beyond-the-gluten-free-diet-a-new-era-in-celiac-disease-treatment Jennifer C. Smith-Parker BioSpace Insights In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn Geller, the Celiac Disease Foundation; and Dr. Paul Lizzul, AnaptysBio, about the challenges and opportunities facing celiac disease treatment. Thu, 11 Dec 2025 10:19:11 GMT https://www.biospace.com/drug-development/beyond-the-gluten-free-diet-a-new-era-in-celiac-disease-treatment https://www.biospace.com/rosnilimab-shows-promise-as-a-potential-next-generation-ra-therapy A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study Mon, 15 Sep 2025 05:00:00 GMT https://www.biospace.com/rosnilimab-shows-promise-as-a-potential-next-generation-ra-therapy https://www.biospace.com/business/biospace-honors-40-under-40-winners-whose-impact-reflects-industrys-grit Angela Gabriel The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study. Tue, 07 Oct 2025 11:00:00 GMT https://www.biospace.com/business/biospace-honors-40-under-40-winners-whose-impact-reflects-industrys-grit https://www.biospace.com/press-releases/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-145-million-in-private-placement Mon, 30 Mar 2026 04:22:26 GMT https://www.biospace.com/press-releases/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-145-million-in-private-placement https://www.biospace.com/press-releases/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics Mon, 30 Mar 2026 04:22:34 GMT https://www.biospace.com/press-releases/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics https://www.biospace.com/press-releases/first-tracks-biotherapeutics-debuts-on-nasdaq-to-advance-therapies-for-autoimmune-diseases Mon, 20 Apr 2026 15:03:09 GMT https://www.biospace.com/press-releases/first-tracks-biotherapeutics-debuts-on-nasdaq-to-advance-therapies-for-autoimmune-diseases https://www.biospace.com/press-releases/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations Mon, 20 Apr 2026 15:06:55 GMT https://www.biospace.com/press-releases/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations